Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma

Blood

Volumn 126, Issue 11, 2015, Pages 1394-1397

  Celegato, Marta ^a   Borghese, Cinzia ^a   Casagrande, Naike ^a   Mongiat, Maurizio ^a   Kahle, Xaver U ^b   Paulitti, Alice ^a   Spina, Michele ^a   Colombatti, Alfonso ^a   Aldinucci, Donatella ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; CASPASE 3; CD30 LIGAND; CD40 ANTIGEN; CD40 LIGAND; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; NOTCH1 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PATIENT; CLASSICAL HODGKIN LYMPHOMA; DNA FRAGMENTATION; DRUG CYTOTOXICITY; HUMAN; INFLAMMATORY CELL; LETTER; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HODGKIN DISEASE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AURANOFIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HODGKIN DISEASE; HUMANS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942509797     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-660365     Document Type: Letter

References (10)

1. von Tresckow B, Diehl V. An update on emerging drugs for Hodgkin lymphoma. Expert Opin Emerg Drugs. 2014;19(2):215-224.
2. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res. 2012;72(5):1055-1058.
3. Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs R D. 2015;15(1):13-20.
4. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221(3):248-263.
5. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9):3398-3403.
6. Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012;122(10):3439-3447.
7. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679-692.
8. Fiskus W, Saba N, Shen M, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014;74(9):2520-2532.
9. Marinaccio C, Nico B, Maiorano E, Specchia G, Ribatti D. Insights in Hodgkin Lymphoma angiogenesis. Leuk Res. 2014;38(8):857-861.
10. He MF, Gao XP, Li SC, et al. Anti-angiogenic effect of auranofin on HUVECs in vitro and zebrafish in vivo. Eur J Pharmacol. 2014;740:240-247.